7 years ago

Crescendo Biologics Secures $70M in Series B to Advance Cancer Treatment

  • Crescendo Biologics, a UK-based developer of multi-functional biologics, has raised $70 million in Series B financing

  • The round was led by Andera Partners with participation from Biodiscovery V, Quan Capital, Sofinnova Partners, IP Group, EMBL and Takeda Ventures

  • The company plans to use the funds to advance its lead program, CB307, into clinical trials and expand its internal pipeline of products.

      • ProblemHealthcare

      "making cancer treatments more effective by amplifying the body's immune response"

      Solution

      "developing multi-functional biologics that stimulate the local activation of tumour-specific T-cells, leading to enhanced tumour control and reduced systemic side effects"

      Covered on